CSF Biomarkers and Cognitive Impairment in Multiple Sclerosis
Author Information
Author(s): Barba Lorenzo, Gaetani Lorenzo, Sperandei Silvia, Di Sabatino Elena, Abu-Rumeileh Samir, Halbgebauer Steffen, Oeckl Patrick, Steinacker Petra, Parnetti Lucilla, Di Filippo Massimiliano, Otto Markus
Hypothesis
To assess the role of CSF synaptosomal-associated protein 25 (SNAP-25), β-synuclein, neurogranin and neurofilament light chain protein (NfL) in patients with early relapsing MS with and without cognitive impairment.
Conclusion
Lower CSF synaptic biomarker levels were found in PwMS with longer disease duration and lower brain volumes and may identify PwMS at risk of cognitive impairment.
Supporting Evidence
- CSF synaptic protein levels did not discriminate between MS subjects and patients with other neurological diseases.
- Lower biomarker levels were correlated with longer disease duration and lower brain volumes.
- Significantly lower CSF SNAP-25, β-synuclein, and neurogranin levels were found in PwMS with cognitive impairment.
Takeaway
This study looked at special proteins in the fluid around the brain of people with multiple sclerosis to see if they can help understand memory problems. They found that lower levels of these proteins might mean a higher chance of having memory issues.
Methodology
We measured CSF SNAP-25, β-synuclein, and neurogranin in 48 untreated PwMS and 50 controls with other neurological diseases and tested their associations with neuropsychological and MRI data.
Limitations
The main limitation of this study is the small sample size and the incomplete data concerning MRI.
Participant Demographics
The cohort included 50 subjects with other neurological diseases (mean age: 49.5 years, 60% females) and 48 PwMS (mean age: 37.3 years, 68.8% females).
Statistical Information
P-Value
p=0.009
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website